이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IRRAS 과거 수익 실적

이 회사의 최신 수익 보고서는 아직 처리 중입니다.

과거 기준 확인 0/6

IRRAS의 수입은 연평균 -6.1%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 17%의 비율로 증가했습니다. 매출은 연평균 47.2%의 비율로 증가해 왔습니다.

주요 정보

-6.1%

수익 성장률

38.2%

EPS 성장률

Medical Equipment 산업 성장	6.2%
매출 성장률	47.2%
자기자본 수익률	-455.7%
순이익	-455.7%
다음 실적 업데이트	21 Feb 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

IRRAS 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:IRRAS 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 23	43	-196	153	49
31 Mar 23	43	-193	145	52
31 Dec 22	40	-167	130	46
30 Sep 22	37	-164	120	39
30 Jun 22	32	-141	106	29
31 Mar 22	27	-131	101	24
31 Dec 21	22	-136	93	24
30 Sep 21	18	-131	90	27
30 Jun 21	14	-135	88	29
31 Mar 21	10	-140	87	28
31 Dec 20	7	-136	90	29
30 Sep 20	8	-134	88	28
30 Jun 20	7	-139	87	26
31 Mar 20	7	-147	90	28
31 Dec 19	5	-151	89	30
30 Sep 19	2	-165	102	28
30 Jun 19	1	-171	111	30
31 Mar 19	0	-160	108	29
31 Dec 18	6	-139	103	24
30 Sep 18	7	-112	83	26
30 Jun 18	18	-78	72	17
31 Mar 18	18	-67	66	15
31 Dec 17	12	-61	56	13
30 Sep 17	11	-48	48	7
31 Dec 16	0	-32	27	3
31 Dec 15	0	-13	7	4

양질의 수익: IRRAS 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IRRAS 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IRRAS 은(는) 수익성이 없으며 지난 5년 동안 연간 6.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IRRAS 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IRRAS 은(는) 수익성이 없어 지난 해 수익 성장을 Medical Equipment 업계( 41.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IRRAS 현재 수익성이 없기 때문에 마이너스 자본 수익률( -455.69% )을 갖습니다.

IRRAS 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

New 90-day high: kr6.98

Analysts increase revenue estimates to kr27.5m

First half earnings released

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률